黑料网

Journal of Pharmacokinetics & Experimental Therapeutics
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Pharmacokinet Exp Ther,

Pharmacotherapeutics to Restore Neurological Function Compromised by Central Demyelination

Talia Sheikh*
Department of Parmaceutical, Shivlingeshwar College of Pharmacy, Mumbai, India
*Corresponding Author : Talia Sheikh, Department of Parmaceutical, Shivlingeshwar College of Pharmacy, Mumbai, India, Email: talia.sheikh@gmail.com

Received Date: Apr 19, 2023 / Published Date: Jun 27, 2023

Abstract

The multiple sclerosis and Parkinson’s complaint are neurodegenerative complaint which effect on the central nervous system. Which loss the collaboration between brain and body multiple sclerosis is the progressive, autoimmune complaint. It occurs when your vulnerable system attack myelin cell in your brain and spinal cord. Parkinson’s complaint is caused by the loss of dopamine in a part of your brain called substantial nigra, which causes and cure are unknown. MS complaint are generally occurs in youthful adult i.e. 20 to 40 times where as Parkinson’s complaint generally occurs in old persons i.e. 60 times. Both the complaint don't do in same person, both complaint loss the collaboration of brain and body related to gait dysfunction. Dalfampridine is one of the available treatments for to ameliorate the walking in MS and Parkinson’s complaint related to gait dysfunction. Dalfampridine is the oral potassium channel blocker which was lately approved by FDA for sympathomimetic treatment in MS. Dalfampridine which acts on central and supplemental nervous system enhances conduction in demyelinated axon and improves waking capability of MS case.

Citation: Sheikh T (2023) Pharmacotherapeutics to Restore Neurological Function Compromised by Central Demyelination. J Pharmacokinet Exp Ther 7: 206.

Copyright: © 2023 Sheikh T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top